The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients

Clinical Nephrology

Volumn 80, Issue 1, 2013, Pages 17-22

  Soriano, Sagrario ^a,b   Ojeda, Raquel ^a,b   Rodríguez, Mencarnación ^a,b   Almadén, Yolanda ^a,b   Rodríguez, Mariano ^a,b   Martín Malo, Alejandro ^a,b   Aljama, Pedro ^a,b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

End stage renal disease; FGF23; Lanthanum carbonate; Phosphate binders

Indexed keywords

CALCIUM; CALCIUM CARBONATE; FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; PHOSPHATE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; OUTPATIENT DEPARTMENT; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; URINARY EXCRETION;

ADULT; AGED; AGED, 80 AND OVER; CALCIUM; CALCIUM CARBONATE; CHELATING AGENTS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; LANTHANUM; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; STATISTICS, NONPARAMETRIC; VITAMIN D;

EID: 84880415413     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107764     Document Type: Article

References (18)

1. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005; 16: 520-528.
2. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW; PREPARE study group. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007; 22: 2909-2916.
3. Eddington H, Hoefield R, Sinha S, Chrysochou C, Lane B, Foley RN, Hegarty J, New J, O'Donoghue DJ, Middleton RJ, Kalra PA. Serum phosphate and mortality in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010; 5: 2251-2257.
4. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G; Cholesterol And Recurrent Events Trial Investigators. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005; 112: 2627-2633.
5. Larsson TE, Olauson H, Hagström E, Ingelsson E, Arnlöv J, Lind L, Sundström J. Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community. Arterioscler Thromb Vasc Biol. 2010; 30: 333-339.
6. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305: 2432-2439.
7. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M; HOST Investigators. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol. 2011; 22: 1913-1922.
8. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant. 2010; 25: 3983-3989.
9. González-Parra E, González-Casaus ML, Galán A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant. 2011; 26: 2567-2571.
10. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moysés RM. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol. 2010; 5: 286-291.
11. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med. 2010; 362: 1312-1324.
12. Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, Takahashi H, Hirawa N, Oogushi Y, Miyata T, Kobayashi H, Fukagawa M, Saito A. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis. 2011; 57: 422-431.
13. Isakova T, Gutiérrez OM, Smith K, Epstein M, Keating LK, Jüppner H, Wolf M. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant. 2011; 26: 584-591.
14. Ix JH, Shlipak MG, Wassel CL, Whooley MA. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant. 2010; 25: 993-997.
15. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F; MMKD Study Group. Kuen E, König P, Kraatz G, Mann JF, Müller GA, Köhler H, Riegler P: Fibroblast growth factor-23 predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMMKD) Study. J Am Soc Nephrol. 2007; 18: 613-620.
16. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009; 119: 2545-2552.
17. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F; MMKD Study Group. Kuen E, König P, Kraatz G, Mann JF, Müller GA, Köhler H, Riegler P:FGF-23 predicts progression of chronic kidney disease: The mild to moderate kidney disease (MMKD) Study. J Am Soc Nephrol. 2007; 18: 2600-2608.
18. Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol. 2009; 4: 178-185